Emergent Biosolutions (EBS) Research Coverage Started at Goldman Sachs Group

Equities research analysts at Goldman Sachs Group started coverage on shares of Emergent Biosolutions (NYSE:EBS) in a note issued to investors on Wednesday, Marketbeat reports. The firm set a “neutral” rating and a $55.00 price target on the biopharmaceutical company’s stock. Goldman Sachs Group’s target price points to a potential upside of 8.31% from the stock’s current price.

A number of other equities research analysts also recently commented on EBS. Wells Fargo & Co reaffirmed an “outperform” rating and set a $43.00 target price (up previously from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. Chardan Capital lifted their target price on Emergent Biosolutions from $47.00 to $53.00 and gave the stock a “buy” rating in a report on Tuesday, January 16th. Finally, Zacks Investment Research downgraded Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 11th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $51.00.

Emergent Biosolutions (NYSE:EBS) traded up $0.01 during trading on Wednesday, hitting $50.78. The company had a trading volume of 252,993 shares, compared to its average volume of 328,761. The company has a debt-to-equity ratio of 0.38, a current ratio of 7.37 and a quick ratio of 6.46. Emergent Biosolutions has a 12-month low of $27.94 and a 12-month high of $51.25. The firm has a market capitalization of $2,090.00, a P/E ratio of 31.74, a price-to-earnings-growth ratio of 1.04 and a beta of 1.29.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the Zacks’ consensus estimate of $0.41 by $0.32. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The firm had revenue of $149.43 million during the quarter, compared to the consensus estimate of $124.55 million. During the same quarter in the previous year, the company posted $0.56 earnings per share. The company’s revenue was up 4.6% compared to the same quarter last year. analysts expect that Emergent Biosolutions will post 1.7 EPS for the current fiscal year.

In related news, Chairman Fuad El-Hibri sold 40,000 shares of Emergent Biosolutions stock in a transaction that occurred on Tuesday, November 14th. The stock was sold at an average price of $40.37, for a total transaction of $1,614,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Abdun-Nabi sold 31,508 shares of Emergent Biosolutions stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $42.77, for a total value of $1,347,597.16. Following the transaction, the chief executive officer now owns 215,642 shares of the company’s stock, valued at $9,223,008.34. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 211,481 shares of company stock valued at $9,154,650. 16.50% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of EBS. Alliancebernstein L.P. increased its holdings in Emergent Biosolutions by 91.5% during the 2nd quarter. Alliancebernstein L.P. now owns 94,792 shares of the biopharmaceutical company’s stock worth $3,214,000 after purchasing an additional 45,280 shares during the period. Martingale Asset Management L P bought a new stake in Emergent Biosolutions in the second quarter valued at about $452,000. Riverhead Capital Management LLC increased its holdings in Emergent Biosolutions by 102.8% in the second quarter. Riverhead Capital Management LLC now owns 3,042 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 1,542 shares during the last quarter. TIAA CREF Investment Management LLC increased its holdings in Emergent Biosolutions by 1.0% in the second quarter. TIAA CREF Investment Management LLC now owns 90,099 shares of the biopharmaceutical company’s stock valued at $3,055,000 after buying an additional 933 shares during the last quarter. Finally, Ameriprise Financial Inc. increased its holdings in Emergent Biosolutions by 24.2% in the second quarter. Ameriprise Financial Inc. now owns 275,319 shares of the biopharmaceutical company’s stock valued at $9,336,000 after buying an additional 53,669 shares during the last quarter. Institutional investors and hedge funds own 88.53% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first posted by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.americanbankingnews.com/2018/01/28/emergent-biosolutions-ebs-research-coverage-started-at-goldman-sachs-group.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply